XML 37 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (in shares) at Dec. 31, 2018   23 97,225,810        
Beginning balance at Dec. 31, 2018 $ 87,032,407 $ 0 $ 97,226 $ 707,794,215 $ (620,426,436) $ (528,867) $ 96,269
Issuance of common stock for cash (in shares)     183,200        
Issuance of common stock for cash 907,330   $ 183 907,147      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)     525,000        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (719,397)   $ 525 (719,922)      
Equity component of issuance of convertible notes 15,752,698     15,752,698      
Stock-based compensation 3,432,796     3,432,796      
Acquisition of non-controlling interest in Geneos 3,030,107           3,030,107
Net loss attributable to common stockholders (29,288,867)       (29,219,262)   (69,605)
Unrealized gain (loss) on short-term investments, net of tax 819,177         819,177  
Ending balance (in shares) at Mar. 31, 2019   23 97,934,010        
Ending balance at Mar. 31, 2019 80,966,251 $ 0 $ 97,934 727,166,934 (649,645,698) 290,310 3,056,771
Beginning balance (in shares) at Dec. 31, 2019   23 101,361,034        
Beginning balance at Dec. 31, 2019 5,404,858 $ 0 $ 101,361 742,646,785 (739,785,655) 472,608 1,969,759
Issuance of common stock for cash (in shares)     43,148,952        
Issuance of common stock for cash 208,241,933   $ 43,149 208,198,784      
Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)     1,405,114        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 3,100,703   $ 1,405 3,099,298      
Stock-based compensation 4,001,553     4,017,761     (16,208)
Acquisition of non-controlling interest in Geneos 2,169,998           2,169,998
Net loss attributable to common stockholders (33,135,404)       (32,541,054)   (594,350)
Unrealized gain (loss) on short-term investments, net of tax (1,929,538)         (1,929,538)  
Ending balance (in shares) at Mar. 31, 2020   23 145,915,100        
Ending balance at Mar. 31, 2020 $ 187,854,103 $ 0 $ 145,915 $ 957,962,628 $ (772,326,709) $ (1,456,930) $ 3,529,199